"Microplastics are becoming an unavoidable part of our environment, and their presence in human lung tissue is a significant finding, though the exact relationship with lung cancer is still under investigation."
A recent study examining lung tissue samples from individuals undergoing bronchoscopy has revealed the presence of microplastic particles in a substantial majority of participants. Notably, the research observed a higher prevalence and greater quantity of these microscopic plastic fragments in patients subsequently diagnosed with lung cancer compared to those without. While this association is compelling, the study’s lead investigator emphasizes that the findings do not establish a causal link, suggesting that diseased lungs may simply accumulate particles differently. This groundbreaking research, presented at a conference abstract, highlights the pervasive nature of microplastics and prompts further investigation into their potential impact on respiratory health.
The study, conducted by researchers at University College Dublin School of Medicine and the University of Thessaly, involved the examination of lung samples from 100 individuals undergoing bronchoscopy at the University Hospital of Larissa in Greece. The procedure was performed to investigate existing lung symptoms, with diagnoses made after sample collection. Microplastic particles were detected in 70 percent of the lung samples. A more detailed analysis revealed that detectable microplastics were present in airway wash samples from 66 percent of patients diagnosed with lung cancer, a significantly higher rate than the 46 percent observed in patients without cancer. Across all samples, investigators quantified a total of 232 particles. When both airway wash and tissue samples were analyzed collectively for each patient, individuals with lung cancer were not only more likely to have detectable microplastics but also exhibited a higher overall burden of these particles.
However, a critical caveat underscores the study’s findings: the direction of cause remains genuinely open. Dr. Ilias Dimeas, the lead investigator, has publicly stated that diseased lungs might retain particles differently than healthy ones, rather than the particles directly contributing to cancer. Tumors can alter the architectural structure and clearance mechanisms of surrounding lung tissue. Consequently, a lung that is less efficient at clearing particles due to disease progression or other factors will naturally accumulate more of them. This interpretation suggests that the increased microplastic presence could be a consequence of the disease rather than a contributing cause. The study’s design, which measured both microplastic presence and cancer diagnosis concurrently, cannot differentiate between these two possibilities.
The methodology involved each participant providing a bronchoalveolar lavage sample, where saline is used to rinse a section of the lung. Half of the participants also provided a small tissue sample. Dr. Dimeas remarked, "Microplastics have become an unavoidable part of our environment," adding that the long-term effects of their entry into the human body are still largely unknown. This observation underscores the ubiquitous nature of microplastics, which are now found in various environmental compartments, including air, water, and food.
An unexpected finding emerged regarding the distribution of microplastics within the lungs. When researchers compared the two types of samples (airway wash and tissue) from the same individuals, they observed an inverse relationship. Patients with a higher concentration of microplastics in their airway wash samples tended to have lower concentrations in their corresponding tissue samples, and vice versa. This pattern suggests that microplastics are not uniformly distributed throughout the lung. Different regions of the lung may retain these particles with varying degrees of efficiency. This discovery carries significant methodological implications for the broader field of microplastic research. Studies that rely on sampling only one compartment of the lung may be capturing a narrow view of the overall microplastic burden, potentially leading to an incomplete understanding of exposure levels.
The most commonly identified polymer types were polypropylene and polyethylene. These plastics are widely used in everyday items, including packaging, textiles, household materials, and consumer goods, reflecting their pervasive presence in modern life. The study was notably conducted without external funding, utilizing the resources available within the university’s respiratory medicine department. This self-funded nature highlights the researchers’ commitment to exploring this critical public health question.
It is crucial to acknowledge the limitations of this study in establishing definitive evidence. The research involved 100 participants from a single hospital and has been presented as a conference abstract, meaning it has not yet undergone formal peer review. The study captured an association at a single point in time, and the participants were already symptomatic enough to require a bronchoscopy, meaning they do not represent the general healthy population. Furthermore, the researchers indicated that additional data were gathered after the abstract submission, suggesting that published figures may evolve.
The comparison group in this study is also noteworthy. The 50 patients who did not receive a cancer diagnosis were also undergoing bronchoscopy for lung symptoms. Therefore, this study does not compare microplastic presence in cancerous lungs against entirely healthy lungs. While this design choice helps to reduce certain confounding factors, it also raises questions about the generalizability of the findings to broader populations.
Several key variables remain unresolved, with smoking being the most prominent. Smoking is the leading cause of lung cancer and significantly impacts particle clearance mechanisms in the lungs. The available presentation materials do not detail how smoking history was accounted for in the comparison between the cancer and non-cancer groups. This omission represents a significant gap that needs to be addressed in the full publication of the study. Another open question pertains to occupational exposure. Individuals working in industries such as textile manufacturing, plastics processing, or construction are known to breathe measurably higher levels of airborne particles than the general population, and their potential contribution to microplastic burden warrants further investigation.
Professor Barbara Hoffmann, chair of the society’s Advocacy Council at the University of Düsseldorf, who was not involved in the research, emphasized the need for more extensive research to fully understand the role microplastics might play in various lung diseases, including cancer. "These tiny pieces of plastic are infiltrating many parts of the body," she stated, while reiterating that smoking remains the most significant risk factor for lung cancer, and air pollution is now also an established cause.
From a practical standpoint for households, the current findings do not translate into immediate changes in medical practice or personal behavior. There is currently no medical test for microplastics in the lungs, nor are there any treatments to remove them. Any claims of tests or "detox" programs for microplastic exposure should be viewed with skepticism, as they are not supported by scientific evidence.
The exposures implicated in this study are not primarily driven by individual consumer choices. If microplastics are entering the lungs through inhaled air, as the researchers hypothesize, then indoor and outdoor air quality are the primary pathways. Simply changing water bottles or other single-use plastic items is unlikely to address this route of exposure. Measures that can plausibly reduce airborne particle exposure indoors, such as using HEPA filters and ensuring adequate ventilation, are already recommended for mitigating the impact of various pollutants and are supported by existing evidence for improving respiratory health. These recommendations are consistent with policy-level arguments being made by organizations focused on environmental health.
The established priorities for reducing lung cancer risk remain unchanged. These include not smoking, quitting smoking for those who do, testing homes for radon, and adhering to recommended screening guidelines. The U.S. Preventive Services Task Force advises annual low-dose CT screening for adults aged 50 to 80 who have a history of smoking 20 pack-years or more and currently smoke or have quit within the past 15 years. Lung cancer continues to be among the leading causes of cancer death in the United States, underscoring the importance of these evidence-based preventive measures.
Drs. Dimeas and his colleagues are continuing their laboratory work to investigate how the identified types of plastics might interact with lung cells. They are also conducting separate analyses of samples from patients with chronic lung disease to determine whether microplastics contribute to lung scarring and disease progression. The results of these ongoing investigations are anticipated and will be crucial in further elucidating the complex relationship between microplastics and respiratory health.
Key Questions Answered:
What did the study find?
Among 100 patients undergoing bronchoscopy, 70 percent had detectable microplastics in their lung samples. Patients subsequently diagnosed with lung cancer showed a higher prevalence (66 percent in airway samples) and a greater total quantity of these particles compared to those without cancer (46 percent in airway samples).
Does this show microplastics cause lung cancer?
No. The lead investigator has suggested that diseased lungs may simply retain particles differently than healthy lungs. The study’s design, measuring both factors simultaneously, cannot establish a definitive direction of cause.
What kinds of plastic were found?
Polypropylene and polyethylene were the most common types of microplastics identified. These polymers are widely used in packaging, textiles, and numerous consumer products.
Who were the comparison patients?
The comparison group consisted of 50 patients from the same hospital who were also undergoing bronchoscopy for lung symptoms but were not diagnosed with cancer. They were not healthy volunteers.
Is there a test for microplastics in the lungs?
Currently, there is no medical test to detect microplastics in the lungs. There are no established treatments to remove them, and no products are scientifically proven to do so.
What was the unexpected finding about distribution?
An unexpected observation was the inverse relationship between microplastic counts in airway wash samples and tissue samples. This suggests that microplastics are not distributed uniformly throughout the lung, with different regions exhibiting varying retention capabilities.
What still reduces lung cancer risk?
The most effective measures for reducing lung cancer risk remain not smoking, quitting smoking, testing homes for radon, and undergoing low-dose CT screening for eligible individuals (adults aged 50 to 80 with a 20 pack-year smoking history who currently smoke or quit within the past 15 years).
